Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). (DV)
Primary Purpose
Hypogonadism, Male
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
LPCN 1021
Sponsored by
About this trial
This is an interventional treatment trial for Hypogonadism, Male
Eligibility Criteria
Inclusion Criteria:
- Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy.
- Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired).
- Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility.
Exclusion Criteria:
- History of significant sensitivity or allergy to androgens, or product excipients.
- Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up.
- Abnormal prostate digital rectal examination (DRE) with palpable nodule(s).
- Subjects with symptoms of moderate to severe benign prostatic hyperplasia.
- Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis
- Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).
- History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
- History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.
- History of stroke or myocardial infarction within the past 5 years.
- History of or current or suspected prostate or breast cancer.
- History of untreated and severe obstructive sleep apnea.
- History of long QT syndrome (QTc > 450) or unexplained sudden death in a first degree relative (parent, sibling, or child).
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Oral testosterone undecanoate, LPCN 1021
Arm Description
Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
Outcomes
Primary Outcome Measures
Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range
The primary efficacy endpoint and analysis for this study was the percentage of LPCN 1021 treated subjects who had achieved a 24-hour average serum T concentration within the normal range of 300 to 1080 ng/dL at Visit 4, (Day 24 ± 4 days).
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03242590
Brief Title
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Acronym
DV
Official Title
Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
December 2016 (Actual)
Primary Completion Date
March 2017 (Actual)
Study Completion Date
July 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lipocine Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypogonadism, Male
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
95 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oral testosterone undecanoate, LPCN 1021
Arm Type
Experimental
Arm Description
Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
Intervention Type
Drug
Intervention Name(s)
LPCN 1021
Intervention Description
Oral testosterone undecanoate
Primary Outcome Measure Information:
Title
Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range
Description
The primary efficacy endpoint and analysis for this study was the percentage of LPCN 1021 treated subjects who had achieved a 24-hour average serum T concentration within the normal range of 300 to 1080 ng/dL at Visit 4, (Day 24 ± 4 days).
Time Frame
Following 24 days of treatment
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Serum total T below 300 ng/dL based on 2 consecutive blood samples obtained between 6 and 10 AM, on two separate days at approximately the same time of day, following an appropriate washout of current androgen replacement therapy.
Subjects should be diagnosed to be primary (congenital or acquired) or secondary hypogonadal (congenital or acquired).
Naïve to androgen replacement or has discontinued current treatment and completed adequate washout of prior androgen therapy. Washout must be completed prior to collection of baseline serum T samples to determine study eligibility.
Exclusion Criteria:
History of significant sensitivity or allergy to androgens, or product excipients.
Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up.
Abnormal prostate digital rectal examination (DRE) with palpable nodule(s).
Subjects with symptoms of moderate to severe benign prostatic hyperplasia.
Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis
Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).
History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.
History of stroke or myocardial infarction within the past 5 years.
History of or current or suspected prostate or breast cancer.
History of untreated and severe obstructive sleep apnea.
History of long QT syndrome (QTc > 450) or unexplained sudden death in a first degree relative (parent, sibling, or child).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony DelConte, MD
Organizational Affiliation
Lipocine Inc.
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34994093
Citation
DelConte A, Papangkorn K, Kim K, Bruno BJ, Chidambaram N, Khera M, Goldstein I, Kohler TS, Miner M, Dobs AS, Patel MV. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022 May;10(4):669-676. doi: 10.1111/andr.13153. Epub 2022 Jan 18.
Results Reference
derived
Learn more about this trial
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
We'll reach out to this number within 24 hrs